Roche Holding AG (RHHVF)
| Market Cap | 349.49B +40.5% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.88 |
| Forward PE | 16.78 |
| Dividend | 20.68 (4.77%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 5,187 |
| Open | 440.67 |
| Previous Close | 454.00 |
| Day's Range | 432.49 - 451.47 |
| 52-Week Range | 306.44 - 490.33 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and suppor...
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Roche upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Roche (RHHBY) to Overweight from Equal Weight with a price target of $63, up from $46. The firm says the company offers a “strong mix of visible…
Roche launches two new cyclospora tests as US outbreak widens
Roche said on Thursday it launched two new tests to detect cyclospora, as U.S. cyclosporiasis cases climbed to record levels this year making the foodborne-illness outbreak one of the largest in the...
Roche expands cyclospora testing portfolio to support U.S. public health response
Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories. The new tests expand the Roche cyclospora portfolio, pro...
Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer
Labcorp (LH) announced the nationwide availability of Roche’s (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PT...
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, ...
Genprex announces collaboration with Roche Diagnostics
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclini...
Roche announces EMA’s CHMP recommended approval of Susvimo
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascu...
Roche receives FDA 510(k) clearance for cobas BV/CV assay
Roche (RHHBY) announced that it has received U.S. FDA 510(k) clearance for its cobas BV/CV assay. This molecular diagnostic test provides results for both Bacterial vaginosis and Candida vaginitis fro...
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit...
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv...
Roche Holding AG Earnings Call Transcript: H1 2026
Core operating profit rose 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high with five FDA priority reviews and major launches in diagnostics and obesity. Currency headwinds and China reforms continue to impact results.
Roche Holding AG Quarterly report: H1 2026
Roche Holding AG has published its H1 2026 quarterly earnings report on July 23, 2026.
Roche Holding AG Slides: H1 2026
Roche Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 23, 2026.
Roche Holding AG Earnings release: H1 2026
Roche Holding AG released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche Backs Full-Year View as First-Half Sales Rise
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation seque...
MaxCyte enters technology license partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides…
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
Roche (RHHBY) announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1. Malarek currently serves as Chief Executive Officer of Foundation Me...
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America
Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end o...
Genentech granted priority review for Gazyva sBLA by FDA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted priority review to the company’s supplemental biologics license application, or sBLA, for Gazyva for the treatment of primary…
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Appl...